tradingkey.logo

MaxCyte Inc

MXCT
查看詳細走勢圖
1.635USD
+0.135+9.00%
交易中 美東報價延遲15分鐘
174.36M總市值
虧損本益比TTM

MaxCyte Inc

1.635
+0.135+9.00%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+9.00%

5天

+7.57%

1月

-2.10%

6月

-19.85%

今年開始到現在

-60.70%

1年

-61.44%

查看詳細走勢圖

TradingKey MaxCyte Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

MaxCyte Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名105/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價6.34。中期看,股價處於平穩狀態。近一個月,市場表現較差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

MaxCyte Inc評分

相關信息

行業排名
105 / 208
全市場排名
242 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 7 分析師
買入
評級
6.344
目標均價
+309.29%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

MaxCyte Inc亮點

亮點風險
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
業績增長期
公司處於發展階段,最新年度總收入38.63M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入38.63M美元
估值高估
公司最新PE估值-3.49,處於3年歷史高位
機構減倉
最新機構持股82.96M股,環比減少17.02%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉9.86K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.71

MaxCyte Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

MaxCyte Inc簡介

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
公司代碼MXCT
公司MaxCyte Inc
CEOMasoud (Maher)
網址https://www.maxcyte.com/

常見問題

MaxCyte Inc(MXCT)的當前股價是多少?

MaxCyte Inc(MXCT)的當前股價是 1.635。

MaxCyte Inc 的股票代碼是什麼?

MaxCyte Inc的股票代碼是MXCT。

MaxCyte Inc股票的52週最高點是多少?

MaxCyte Inc股票的52週最高點是5.200。

MaxCyte Inc股票的52週最低點是多少?

MaxCyte Inc股票的52週最低點是1.260。

MaxCyte Inc的市值是多少?

MaxCyte Inc的市值是174.36M。

MaxCyte Inc的淨利潤是多少?

MaxCyte Inc的淨利潤為-41.05M。

現在MaxCyte Inc(MXCT)的股票是買入、持有還是賣出?

根據分析師評級,MaxCyte Inc(MXCT)的總體評級為買入,目標價格為6.344。

MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是多少

MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是-0.430。
KeyAI